Natural Monoterpenes against Atherosclerosis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Rita Xu and Version 1 by Chao Zhong.

Traditional herbal medicines based on natural products play a pivotal role in preventing and managing atherosclerotic diseases, which are among the leading causes of death globally. Monoterpenes are a large class of naturally occurring compounds commonly found in many aromatic and medicinal plants. Emerging evidence has shown that monoterpenes have many biological properties, including cardioprotective effects.

  • natural products
  • monoterpenes
  • atherosclerosis

1. Introduction

Atherosclerosis is the major underlying pathological basis for coronary artery disease, cerebrovascular disease, and peripheral arterial disease, which causes significant morbidity and mortality worldwide [1,2,3,4][1][2][3][4]. A spectrum of mechanisms is involved in the initiation and progression of atherosclerosis, including endothelial dysfunction, abnormal lipid metabolism, oxidative stress, and inflammation [3,5,6][3][5][6]. Additionally, a wide array of risk factors such as dyslipidemia, obesity, diabetes, hypertension, aging, and smoking are recognized to be associated with atherosclerosis [7], and the interplay between them makes atherosclerosis a complex condition. Over the past decades, despite significant advances in prevention therapies using contemporary intervention and pharmacologic agents against atherosclerosis, the burden of ischemic cardiovascular conditions remains substantial [8,9][8][9]. Therefore, to better cope with the life-threatening atherosclerotic cardiovascular disease (ASCVD), it is urgent to seek new effective therapeutic agents targeting atherosclerosis without marked side effects.
Natural products derived from plants remain attractive sources of molecular entities for developing novel medicinal and therapeutic agents [10]. Due to fewer adverse effects and lower cost of natural compounds compared with chemotherapeutic agents, therapies based on natural products have long been widely used in traditional medicines to treat ASCVD in China and many other Asian countries [11,12][11][12]. Terpenes represent a large class of plant-derived secondary metabolites with five-carbon isoprene (C5H8) units as their primary structural component [13]. According to the number of isoprene units within their chemical structure, terpenes can be classified into hemiterpene (C5), monoterpene (C10), sesquiterpene (C15), diterpene (C20), sesterpene (C25), triterpene (C30), and polyterpene (>C30) [13]. The monoterpenes, a major chemical group of terpenes with two isoprene units in their structure, are commonly found in many bioactive essential oils and medicinal plants [14]. It has been well documented that monoterpenes have many biological properties, including anti-bacterial, anti-fungal, anti-oxidative, anti-inflammatory, and anti-tumor activities [14]. Moreover, they are widely utilized in the pharmaceutical preparations, food, and cosmetic industries [15]. Notably, a growing body of evidence has shown that monoterpenes are promising in their potential roles in protecting against cardiovascular disease. For example, geniposide, a well-known iridoid glycoside, has been reported to have remarkable therapeutic potential in managing cardiac fibrosis, cardiac hypertrophy, myocardial ischemia/reperfusion injury, obesity-related cardiac injury, atherosclerosis, ischemic stroke, and hypertension. This makes it an attractive candidate for cardiovascular medicine [16]. In light of the therapeutic potential of monoterpenes in cardiovascular disease, they are involved in an increasing number of patents registered within the cardiovascular field, highlighting the significant role of these natural compounds in developing new drugs intended to prevent and manage cardiovascular disease [18][17].

2. Natural Monoterpenes Modulate Serum Lipid Profile

Hyperlipidemia refers to the dysregulated lipid metabolism manifesting high levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) and a decreased level of high-density lipoprotein cholesterol (HDL-C) in the circulation. Hyperlipidemia is considered a prominent risk factor for the pathophysiology of atherosclerosis [19][18]. In the early stage of atherosclerotic lesions, LDL particles accumulate and undergo modification in the intima of the arterial wall, leading to subsequent monocyte recruitment and cholesterol-laden foam cell formation [3]. Multiple lines of evidence from experimental and clinical studies have established that excessive serum LDL-C is not merely associated with high risk but also a direct underlying mechanism of atherosclerosis [20][19]. Thus, LDL-C is currently an essential target for the intervention of ASCVD. The introduction of statin drugs, which effectively reduce LDL-C, has been the cornerstone for managing hyperlipidemia and ASCVD risk [9]. Nonetheless, safety issues related to statin therapy remain a chief concern because of the associated adverse effects, such as myopathy and hepatotoxicity [21][20], illustrating the need for new therapeutic strategies. 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the biosynthesis of cholesterol, has been a promising target for developing hypolipidemic drugs such as the statins [3]. The expression of HMG-CoA reductase is critically regulated by sterol regulatory element binding protein-2 (SREBP-2), a crucial transcription factor controlling cellular cholesterol homeostasis [22][21]. HMG-CoA reductase is also post-transcriptionally regulated by the ubiquitin-proteasome system, which depends on the insulin-induced gene 1 (Insig) protein and the ubiquitin ligase gp78 [23][22]. A growing body of evidence has demonstrated that many natural monoterpenes improve hypercholesterolemia by targeting HMG-CoA reductase. Linalool is a naturally occurring monoterpene present in essential oils of various aromatic medicinal plants. Oral administration of linalool significantly alleviated high-fat diet (HFD)-induced hyperlipidemia in mice by diminishing plasma TC, TG, and LDL-C with a concomitant reduction of HMG-CoA reductase expression [24][23]. Furthermore, mechanistic studies have found that linalool could reduce the expression of SREBP-2 and enhance Insig expression and ubiquitination of HMG-CoA reductase, thus attenuating SREBP-2-mediated HMG-CoA reductase transcription and accelerating ubiquitin-dependent proteolysis of HMG-CoA reductase [24][23]. Moreover, as a critical energy sensor of cell metabolism, the AMP-activated protein kinase (AMPK) has been implicated in suppressing HMG-CoA reductase. It thus has therapeutic importance for treating hypercholesterolemia [25][24]. Administration of monoterpenes, such as amarogentin, oleuropein, and aucubin, significantly reduces serum TC and LDL-C by activating AMPK, suggesting that the modulation of AMPK/HMG-CoA reductase signaling may contribute to the hypocholesterolemic property of these monoterpenes [26,27,28][25][26][27]. Reverse cholesterol transport (RCT) refers to the delivery of accumulated cholesterol from the blood and the peripheral tissue into the liver for excretion. Manipulation of this process is thus expected to achieve the hypocholesterolemic effect [29][28]. It has been known that low-density lipoprotein receptor (LDLR), scavenger receptor class B type 1 (SR-B1), and ATP-binding cassette G1 (ABCG1) are involved in RCT. Thymoquinone, the major bioactive component in Nigella sativa volatile oil, could serve as a cholesterol-lowering agent by increasing the uptake of serum LDL-C via elevation of hepatic LDLR expression and by inhibiting HMG-CoA reductase-mediated cholesterol synthesis [30][29]. Geniposide, a well-known monoterpenoid derived from the fruit of Gardenia jasminoides, was found to attenuate cholesterol accumulation in the plasma and the liver, at least partly through facilitating RCT via upregulation of LDLR, SR-B1, and ABCG1 in the liver [31][30]. Another critical aspect of cholesterol metabolism is converting cholesterol into bile acids and their subsequent excretion. These processes are critically orchestrated by the farnesoid X receptor (FXR). Specifically, when abundant bile acids are produced, FXR-mediated negative feedback regulation suppresses hepatic bile acid synthesis while accelerating ileal bile acid reabsorption [32,33][31][32]. Therefore, by inducing bile acid synthesis and inhibiting bile acid reabsorption through FXR suppression, more cholesterol can be converted into bile acids with a concomitant enhancement of bile acids excretion, eventually leading to decreased cholesterol and thus improving atherosclerosis. Notably, a recent study showed that FXR suppression is an important mechanism underlying the protective effects of geniposide on cholesterol homeostasis and atherosclerosis, in addition to the regulation of RCT, as mentioned above [31][30]. The administration of geniposide significantly modulated the FXR-small heterodimer partner (SHP)-hepatocyte nuclear factor 4 (HNF-4α)/liver receptor homolog-1 (LRH-1) axis in the liver and the FXR/ileal bile acid-binding protein (I-BABP) axis in the ileum. These effects were associated with the induction of bile acid synthesis and excretion processes in animals fed with or without HFD, suggesting that geniposide exerts a hypocholesterolemic effect by regulating FXR-mediated liver-gut crosstalk of bile acids [31][30]. Similarly, elevation of bile acid excretion and improved serum lipid profile were observed in a rat model of hypercholesterolemia after oral administration of swertiamarin, which is the main constituent of plants such as Enicostemma littorale, making swertiamarin a potent lipid-lowering and atheroprotective agent [34][33].

3. Natural Monoterpenes Protect against Atherosclerosis by Targeting Endothelial Cells

The endothelial cells are integral to the cardiovascular system and function as gatekeepers of vascular health and homeostasis. The dysfunction of vascular endothelial cells has been recognized as a critical component in the pathophysiology of atherosclerosis [48][34]. Mediated by endothelial dysfunction, circulating lipoprotein particles enter the artery wall, facilitating the recruitment of monocytes/macrophages and the formation of atherogenic foam cells, ultimately triggering a series of complex pathogenic processes to promote plaque formation [48][34].

3.1. Attenuation of Endothelial Pro-Inflammatory Activation

Triggered by various cardiovascular risk factors, endothelial cells undergo morphological and functional modifications, termed endothelial activation, manifesting increased expression of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-Selectin, and chemokines/pro-inflammatory cytokines such as interleukin-8 (IL-8), IL-6, tumor necrosis factor-α (TNF-α), and IL-1β. The results of endothelial activation are increased leukocyte adhesion and infiltration into the vascular wall leading to the propagation and development of vascular inflammation [48][34]. Nuclear factor κB (NF-κB) is a master transcription factor responsible for inflammatory responses [49][35]. Peroxisome proliferator-activated receptor Gama (PPARγ) can attenuate inflammatory responses in the cardiovascular system, including endothelial cells. Growing evidence suggests that PPARγ is an upstream regulator of NF-κB in the anti-inflammatory process [50,51][36][37]. Eucalyptol is a monoterpene found naturally in many aromatic plants with anti-inflammatory effects. Pre-treatment with eucalyptol has been reported to suppress the expression of VCAM-1, E-selectin, IL-8, and IL-6 in lipopolysaccharide (LPS)-induced human umbilical vein endothelial cells (HUVECs), and this was achieved by blockade of NF-κB signaling. Importantly, by using PPARγ inhibitor or PPARγ gene silencing, LPS-induced activation of NF-κB and expression of inflammatory mediators in HUVECs could be reversed, suggesting that modulation of the PPARγ/NF-κB axis contributes to eucalyptol-mediated suppression of endothelial pro-inflammatory activation [52][38]. Similarly, several studies have shown that monoterpenes, including citral, citronellol, and genipin, can inhibit adhesion molecule expression in HUVECs and neutrophil/monocyte–endothelial cell adhesion by regulating the PPARγ-dependent NF-κB signaling pathway [53,54,55][39][40][41]. High mobility group box 1 (HMGB1) is a damage-associated molecular pattern (DAMP), secreted from endothelial cells and leukocytes that mediate inflammation, and correlates with the severity of atherosclerosis [56][42]. Paeoniflorin and cornuside, two natural monoterpenoids used in traditional oriental herbal medicine, were found to suppress the expression and release of HMGB1 in LPS- or lysophosphatidylcholine (LPC)-stimulated HUVECs, paralleling with reduced expression of endothelial cell-derived adhesion molecules and inflammatory factors [57,58][43][44]. The underlying mechanism may involve the induction of sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide–dependent protein deacetylase, which plays an important role in deacetylation of HMGB1 and thus inhibits HMGB1 release and subsequent NF-κB activation in HUVECs [57][43]. Additionally, reactive oxygen species (ROS) have been reported to induce the activation of NF-κB to promote the adhesiveness of endothelial cells [59][45]. Using a high glucose-induced HUVECs model, Wang et al. showed that geniposide exhibited a beneficial role in normalizing endothelial pro-inflammatory activation by inhibiting ROS overproduction, NF-κB activation, and monocyte–endothelial cell adhesion [60][46]. Recently, molecular docking analysis combined with in vitro cell culture-based approaches showed that amarogentin isolated from Gentianaceace plants could directly interact with AMPK to block NF-κB-mediated endothelial inflammation, indicating the pivotal role of AMPK/NF-κB in the protective effect of amarogentin on endothelial activation [26][25]. Notably, many monoterpenes with NF-κB inhibitory effects, such as cornuside, paeoniflorin, and geniposide, can attenuate endothelial activation through mitogen-activated protein kinase (MAPK) signaling (p38 MAPK, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK)), another major signaling pathway driving inflammatory response [57,61,62][43][47][48]. Endoplasmic reticulum (ER) stress, autophagy, and inflammation are tightly integrated biological processes in atherosclerosis’s pathogenesis [79][49]. ER homeostasis is crucial in determining cell survival or death based on the cellular stress factors present. When stimulated by pathological insults, intracellular unfolded protein responses can be induced to protect ER homeostasis. However, excessive and prolonged stimuli disturbing ER homeostasis can cause persistent ER stress responses, triggering inflammatory cascades and cell death events [79][49]. Thus, ER stress is acknowledged as a danger signal for inflammation. Paeoniflorin extracted from the traditional Chinese herb Paeonia lactiflora was reported to be able to modulate ER stress during endothelial pro-inflammatory activation [65][50]. Pre-treatment with paeoniflorin significantly reduced the expression of ER stress markers glucose regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), and spliced X-box binding protein-1 (XBP-1), as well as improved ultrastructural abnormalities of the ER. These events ultimately contributed to the attenuation of NF-κB-dependent production of inflammatory mediators in LPS-induced HUVECs [65][50]. Similarly, catalpol, another natural monoterpene, could also alleviate endothelial inflammation, at least in part, by inhibiting ER stress [66][51]. Autophagy is an evolutionarily conserved lysosomal catabolic process engaged in degrading dysfunctional or surplus protein aggregates and organelles to maintain cellular homeostasis. Nevertheless, aberrant autophagy causes detrimental effects on cellular homeostasis and thus leads to the induction of inflammation and facilitates the pathophysiology of atherosclerosis [79][49]. In addition to regulating ER stress, paeoniflorin was found to promote autophagy and attenuate endothelial pro-inflammatory activation through a SIRT1-dependent mechanism [64][52].

3.2. Inhibition of Endothelial Oxidative Stress

Oxidative stress refers to an imbalance favoring the production of ROS over intrinsic antioxidant mechanisms, which leads to extensive cellular and molecular damage. Endothelial cells are susceptible to risk factors of oxidative stress, such as oxidized lipids, homocysteine, angiotensin II, hyperglycemia, and inflammatory mediators. These risk factors result in the overproduction of ROS followed by endothelial cell damage, dysfunction, pro-inflammatory activation, and apoptosis, eventually promoting the development of atherosclerosis [80][53]. Accordingly, targeting endothelial oxidative stress by attenuating ROS overproduction and/or improving intracellular antioxidant activity would be beneficial for protecting against endothelial oxidative injury and atherosclerosis. Studies have demonstrated that many monoterpenes can alleviate endothelial oxidative stress by either inhibiting pro-oxidant enzymes or by enhancing antioxidant enzymes to maintain cellular redox balance. For example, geraniol, paeoniflorin and harpagoside could suppress endothelial ROS production through the downregulation of NADPH oxidases (NOXs) and cyclooxygenase (COX), which are the predominant sources of ROS in the vasculature [81,82,83][54][55][56]. Other monoterpenes, such as thymoquinone, perillaldehyde, citronellal, geniposide, and monotropein, mitigate endothelial oxidative stress by strengthening the activities of antioxidant enzymes, including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) [67,77,84,85,86][57][58][59][60][61]. The nuclear factor E2-related factor 2 (Nrf2) is a central transcription factor responsible for intracellular redox homeostasis [80][53]. Under basal conditions, Nrf2 binds to Kelch ECH associating protein 1 (Keap1) in the cytoplasm, promoting Nrf2 ubiquitination and degradation. Upon oxidative stress stimulation, Nrf2 dissociates from Keap1 and translocates into the nucleus, thereby inducing the expressions of phase II detoxifying enzymes and antioxidant enzymes for cellular defense [80][53]. A recent study demonstrated that paeoniflorin, a traditional Chinese herbal substance belonging to monoterpenoid, suppressed mitochondrial ROS production and restored mitochondrial functional damage in tert-butyl hydroperoxide (TBHP)-induced HUVECs [90][62]. Furthermore, a mechanistic study indicated that paeoniflorin directly interacted with cytoplasm Nrf2, resulting in the nuclear translocation of Nrf2 and activation of Nrf2-mediated antioxidant signaling, thus relieving TBHP-induced endothelial oxidative stress [90][62]. Another traditional Chinese herbal component with atheroprotective effects, geniposide, was found to attenuate H2O2-induced endothelial oxidative stress by activating the Nrf2 antioxidant pathway. Different from the paeoniflorin mentioned above, geniposide stimulated Nrf2 nuclear translocation by modulating AMPK/mechanistic target of rapamycin (mTOR) signaling [68][63]. Similarly, monoterpenes, such as eucalyptol, geraniol, and catalpol, have also been shown to have anti-oxidative stress effects via Nrf2 activation [42,87,92][64][65][66]. miR-21 is an endogenous miRNA implicated in various pathophysiological processes, including cardiovascular disorders [99][67]. Accumulating evidence suggests that the miR-21/phosphatase and tensin homolog (PTEN) pathway regulates cell survival and death in the cardiovascular system, including endothelial cells, which makes miR-21/PTEN a therapeutic target for cardiovascular disease [100,101][68][69]. Zhou et al. reported that pre-treatment with geniposide decreased ox-LDL-induced oxidative stress in HUVECs by reducing NOX2 expression and by upregulating antioxidant enzyme activities [67][57]. Using gain- and loss-of-function approaches, the investigators further revealed that geniposide could modulate the miR-21/PTEN pathway to restore the balance between intracellular oxidant and antioxidant states, thus preventing ox-LDL-induced endothelial oxidative injury [67][57]. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a well-known receptor for ox-LDL that plays a vital role in atherosclerosis. Homocysteine, a risk factor of atherosclerosis, has been reported to induce the expression of LOX-1 in endothelial cells and to promote ROS generation and oxidative injury [102,103][70][71]. Picroside II, a monoterpenoid isolated from traditional Chinese medicine Picrorhiza scrophulariiflora, was reported to counteract homocysteine-induced LOX-1 expression in a SIRT1-dependent manner and thus ameliorated HUVEC oxidative stress [76][72]. In addition, catalpol and monotropein, two naturally occurring monoterpenoids, were found to attenuate endothelial oxidative stress, at least in part, by inhibiting NF-κB activation, suggesting inflammation as a target of these compounds to regulate oxidative stress [66,77][51][58].

3.3. Modulation of Nitric Oxide (NO) Pathway

Endothelium-derived NO plays essential roles in normal endothelial functions. NO is a multifunctional signaling molecule controlling cardiovascular homeostasis, including regulating vasomotor tone, modulation of platelet activation and leukocyte adhesion, and manipulating local cell growth [104][73]. All established risk factors for atherosclerosis, such as hyperlipidemia, diabetes mellitus, hypertension, and smoking, are found to be associated with diminished NO production [105][74]. Emerging evidence has also indicated that NO bioavailability dysfunction is implicated in the initiation and development of atherosclerosis [105][74]. Therefore, improvement of endothelial NO production provides a potential strategy for preventing and managing atherosclerosis. Abundant evidence has demonstrated the implication of modulating the NO pathway in the effect of natural monoterpenes on endothelial dysfunction and atherosclerosis. NO is synthesized by nitric oxide synthase (NOS) using L-arginine as the substrate [104][73]. NOS includes different isoforms that play contrasting roles in atherosclerosis, with endothelial NOS (eNOS) being atheroprotective and inducible NOS (iNOS) being pro-atherogenic [105][74]. Thus, modulating NO by adjusting the eNOS/iNOS ratio is crucial for protecting against endothelial dysfunction and atherosclerosis. Catalpol, a monoterpenoid extracted from the root of the traditional Chinese herb Rehmanniae radix, could maintain the balance of endothelial NO by inhibiting the NF-κB/iNOS pathway and by activating the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt)/eNOS pathway. As a result, catalpol improved cell viability, enhanced endothelial integrity, and reduced inflammatory response in advanced glycation end-product (AGE)-treated endothelial cells [94][75]. Furthermore, two other monoterpenoids, paeoniflorin and eucalyptol, can upregulate SIRT1 expression to regulate the eNOS/iNOS ratio and to protect against endothelial dysfunction [88,93][76][77]. Notably, the activation of eNOS by these monoterpenoids depends on either eNOS Ser1177 phosphorylation [94][75] or upregulation of eNOS expression [88,93][76][77]. Oxidative stress plays a crucial role in determining NO bioavailability [104][73]. During endothelial dysfunction, oxidative stress mediates ONOO− formation and oxidizes eNOS cofactor tetrahydrobiopterin (BH4), causing BH4 deficiency and eNOS uncoupling. Ultimately, it leads to increased ROS generation and reduced NO bioavailability [104][73]. Perillaldehyde, a major component in essential oil isolated from Perilla frutescens that has been used in traditional Chinese medicine, was reported to prevent endothelial dysfunction and to attenuate the growth of atherosclerosis [85][60]. Mechanically, perillaldehyde alleviated ROS-mediated oxidative stress and rescued BH4 deficiency, thereby promoting eNOS recoupling and improving endothelial dysfunction [85][60]. Other monoterpenoids, such as citronellal and aucubin, similarly induced eNOS recoupling and ameliorated vascular endothelial injury through an anti-oxidative mechanism [91,98][78][79].

3.4. Attenuation of Endothelial Apoptosis

Apoptosis is a well-known programmed cell death pathway involved in various physiological and pathological processes. Two molecular pathways are acknowledged to regulate apoptosis: mitochondrial-dependent intrinsic pathway and death receptor-mediated extrinsic pathway. The mitochondrial-dependent apoptosis pathway is induced by cellular damage or stress, which upregulates B cell leukemia/lymphoma 2 (BCL2)-associated agonist of cell death (Bad) and facilitates the insertion of BCL2-associated X protein (Bax) into the mitochondrial outer membrane. This further causes cytochrome c to be released into the cytoplasm, followed by interaction between cytochrome c and apoptotic peptidase activating factor 1 (Apaf-1) to induce apoptosis through caspase activation [106][80]. The extrinsic apoptotic pathway is initiated by binding extracellular death ligands (such as TNF-α) to their respective cell-surface death receptors. The activation of the death receptors results in the formation of the death-inducing signaling complex mediated by an adaptor protein, thereby triggering caspase activation and the apoptosis process [107][81]. While apoptosis serves as a fundamental mechanism for physiological homeostasis, uncontrolled apoptosis may lead to cellular dysfunction and death. It has been observed that increased endothelial apoptosis is closely associated with atherosclerosis, and pro-atherosclerotic factors such as ox-LDL, oxidative stress, and low shear stress have been shown to induce vascular endothelial cell apoptosis [106,108][80][82]. Therefore, inhibition of endothelial apoptosis may represent a promising strategy to cope with atherosclerosis. Accumulating evidence demonstrates the reduction of endothelial apoptosis as one of the mechanisms by which natural monoterpenes protect against endothelial injury and atherosclerosis. The anti-apoptotic effect of monoterpenes involves the modulation of intrinsic and/or extrinsic apoptotic pathways in endothelial cells. For instance, the beneficial impact of geniposide against atherosclerosis and endothelial dysfunction was related to the attenuation of endothelial apoptosis due to upregulation of anti-apoptotic protein Bcl-2, downregulation of pro-apoptotic protein Bax and caspase-3, and maintaining mitochondrial membrane potential [67,68][57][63]. Similarly, many other monoterpenes have also been shown to ameliorate endothelial cell apoptosis by modulating the Bcl-2/Bax ratio, caspase-9, caspase-3, the release of cytochrome c, and mitochondrial function [64,66,77,78,83,90,97,109][51][52][56][58][62][83][84][85]. All this evidence suggests a mitochondrial-dependent intrinsic pathway as a target in the effect of these monoterpenes. Furthermore, the extrinsic apoptotic pathway is likely implicated in the anti-endothelial apoptotic effect of monoterpenes. Monotropein, an active monoterpenoid isolated from the roots of Morinda officinalis, was reported to suppress the phosphorylation of NF-κB and activating protein-1 (AP-1), which further inhibited the expression of pro-inflammatory cytokine TNF-α and reduced cell apoptosis in H2O2-induced HUVECs. These studies indicated that the protective effect of monotropein on endothelial cells might involve the regulation of the TNF-mediated mitochondrial-independent apoptotic pathway [77][58]. Similarly, picroside II, the main active constituent of Picrorhiza scrophulariiflora belonging to monoterpenoid, was found to decrease the caspase-3 activity and the cleaved caspase-3 protein level to inhibit apoptosis in homocysteine-treated HUVECs, which might also be related to the attenuation of TNF-α production [76][72]. In addition, another study showed that harpagoside, a monoterpenoid extracted from the traditional Chinese herb Scrophulariae Radix, prevented angiotensin II (Ang II)-induced endothelial apoptosis via inactivation of caspase-8/caspase-9/caspase-3, suggesting that harpagoside could exert an anti-apoptosis effect by targeting both intrinsic and extrinsic apoptotic pathways [83][56].

References

  1. Herrington, W.; Lacey, B.; Sherliker, P.; Armitage, J.; Lewington, S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ. Res. 2016, 118, 535–546.
  2. Barquera, S.; Pedroza-Tobías, A.; Medina, C.; Hernández-Barrera, L.; Bibbins-Domingo, K.; Lozano, R.; Moran, A.E. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch. Med. Res. 2015, 46, 328–338.
  3. Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgözoğlu, L.; Lewis, E.F. Atherosclerosis. Nat. Rev. Dis. Prim. 2019, 5, 56.
  4. Tervaert, J.W.C. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract. Res. Clin. Rheumatol. 2013, 27, 33–44.
  5. Schaftenaar, F.; Frodermann, V.; Kuiper, J.; Lutgens, E. Atherosclerosis: The interplay between lipids and immune cells. Curr. Opin. Lipidol. 2016, 27, 209–215.
  6. Li, B.; Li, W.; Li, X.; Zhou, H. Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis. Curr. Pharm. Des. 2017, 23, 1216–1227.
  7. Christ, A.; Bekkering, S.; Latz, E.; Riksen, N.P. Long-term activation of the innate immune system in atherosclerosis. Semin. Immunol. 2016, 28, 384–393.
  8. Libby, P.; Bornfeldt, K.E.; Tall, A.R. Atherosclerosis: Successes, surprises, and future challenges. Circ. Res. 2016, 118, 531–534.
  9. Shapiro, M.; Fazio, S. From lipids to inflammation: New approaches to reducing atherosclerotic risk. Circ. Res. 2016, 118, 732–749.
  10. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug. Discov. 2021, 20, 200–216.
  11. Liu, Q.; Li, J.; Hartstone-Rose, A.; Wang, J.; Li, J.; Janicki, J.S.; Fan, D. Chinese Herbal Compounds for the Prevention and Treatment of Atherosclerosis: Experimental Evidence and Mechanisms. Evid.-Based Complement. Altern. Med. 2015, 2015, 752610.
  12. Ai, X.; Yu, P.; Peng, L.; Luo, L.; Liu, J.; Li, S.; Lai, X.; Luan, F.; Meng, X. Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. Front. Pharmacol. 2021, 12, 762654.
  13. Silva, B.I.M.; Nascimento, E.A.; Silva, C.J.; Silva, T.G.; Aguiar, J.S. Anticancer activity of monoterpenes: A systematic review. Mol. Biol. Rep. 2021, 48, 5775–5785.
  14. De Cássia da Silveira e Sá, R.; Andrade, L.N.; de Sousa, D.P. A Review on Anti-Inflammatory Activity of Monoterpenes. Molecules 2013, 18, 1227–1254.
  15. Koziol, A.; Stryjewska, A.; Librowski, T.; Sałat, K.; Gawel, M.; Moniczewski, A.; Lochynski, S. An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes. Mini-Rev. Med. Chem. 2015, 14, 1156–1168.
  16. Li, N.; Li, L.; Wu, H.; Zhou, H. Antioxidative property and molecular mechanisms underlying genipo-side-mediated therapeutic effects in diabetes mellitus and cardiovascular disease. Oxid. Med. Cell Longev. 2019, 2019, 7480512.
  17. Silva, E.A.P.; Carvalho, J.S.; Guimarães, A.G.; Barreto, R.D.S.; Santos, M.R.; Barreto, A.S.; Quintans-Júnior, L.J. The use of terpenes and derivatives as a new perspective for cardiovascular disease treatment: A patent review (2008–2018). Expert Opin. Ther. Pat. 2018, 29, 43–53.
  18. Nelson, R.H. Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Prim. Care Clin. Off. Pract. 2012, 40, 195–211.
  19. Ference, B.A.; Ginsberg, H.N.; Graham, I.; Ray, K.K.; Packard, C.J.; Bruckert, E.; Hegele, R.A.; Krauss, R.M.; Raal, F.J.; Schunkert, H.; et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017, 38, 2459–2472.
  20. Wilkinson, M.J.; Laffin, L.J.; Davidson, M.H. Overcoming toxicity and side-effects of lipid-lowering therapies. Best Pract. Res. Clin. Endocrinol. Metab. 2014, 28, 439–452.
  21. Brown, M.S.; Goldstein, J.L. Sterol regulatory element binding proteins (SREBPs): Controllers of lipid synthesis and cellular uptake. Nutr. Rev. 1998, 56, S1–S3.
  22. Song, B.-L.; Javitt, N.B.; DeBose-Boyd, R.A. Insig-mediated degradation of HMG CoA reductase stimulated by lanosterol, an intermediate in the synthesis of cholesterol. Cell Metab. 2005, 1, 179–189.
  23. Cho, S.Y.; Jun, H.J.; Lee, J.H.; Jia, Y.; Kim, K.H.; Lee, S.J. Linalool reduces the expression of 3-hydroxy-3-methylglutaryl CoA reductase via sterol regulatory element binding protein-2- and ubiquitin-dependent mecha-nisms. FEBS Lett. 2011, 585, 3289–3296.
  24. Loh, K.; Tam, S.; Murray-Segal, L.; Huynh, K.; Meikle, P.J.; Scott, J.W.; van Denderen, B.; Chen, Z.; Steel, R.; LeBlond, N.D.; et al. Inhibition of Adenosine Mono-phosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholes-terolemia and Promotes Hepatic Steatosis and Insulin Resistance. Hepatol. Commun. 2018, 3, 84–98.
  25. Potunuru, U.R.; Priya, K.V.; Varsha, M.S.; Mehta, N.; Chandel, S.; Manoj, N.; Raman, T.; Ramar, M.; Gromiha, M.M.; Dixit, M. Amarogentin, a secoiridoid glycoside, activates AMP- activated protein kinase (AMPK) to exert beneficial vasculo-metabolic effects. Biochim. Biophys. Acta (BBA)-Gen. Subj. 2019, 1863, 1270–1282.
  26. Hadrich, F.; Mahmoudi, A.; Bouallagui, Z.; Feki, I.; Isoda, H.; Feve, B.; Sayadi, S. Evaluation of hypocho-lesterolemic effect of oleuropein in cholesterol-fed rats. Chem. Biol. Interact. 2016, 252, 54–60.
  27. Shen, B.; Zhao, C.; Wang, Y.; Peng, Y.; Cheng, J.; Li, Z.; Wu, L.; Jin, M.; Feng, H. Aucubin inhibited lipid accumulation and oxi-dative stress via Nrf2/HO-1 and AMPK signalling pathways. J. Cell. Mol. Med. 2019, 23, 4063–4075.
  28. Pownall, H.J.; Rosales, C.; Gillard, B.K.; Gotto, A.M. High-density lipoproteins, reverse cholesterol transport and atherogenesis. Nat. Rev. Cardiol. 2021, 18, 712–723.
  29. Al Naqeb, G.; Ismail, M.; Yazan, L.S. Effects of thymoquinone rich fraction and thymoquinone on plasma lipoprotein levels and hepatic low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase genes expression. J. Funct. Foods 2009, 1, 298–303.
  30. Liu, J.; Li, Y.; Sun, C.; Liu, S.; Yan, Y.; Pan, H.; Fan, M.; Xue, L.; Nie, C.; Zhang, H.; et al. Geniposide reduces cholesterol accumulation and increases its excretion by regulating the FXR-mediated liver-gut crosstalk of bile acids. Pharmacol. Res. 2020, 152, 104631.
  31. Chiang, J.Y. Negative feedback regulation of bile acid metabolism: Impact on liver metabolism and diseases. Hepatology 2015, 62, 1315–1317.
  32. Matsubara, T.; Li, F.; Gonzalez, F.J. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 2013, 368, 17–29.
  33. Vaidya, H.; Rajani, M.; Sudarsanam, V.; Padh, H.; Goyal, R. Swertiamarin: A lead from Enico-stemma littorale Blume. for anti-hyperlipidaemic effect. Eur. J. Pharmacol. 2009, 617, 108–112.
  34. Gimbrone, M.A., Jr.; García-Cardeña, G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res. 2016, 118, 620–636.
  35. Hayden, M.; Ghosh, S. NF-κB in immunobiology. Cell Res. 2011, 21, 223–244.
  36. Lim, S.; Lee, K.-S.; Lee, J.E.; Park, H.S.; Kim, K.M.; Moon, J.H.; Choi, S.H.; Park, K.S.; Kim, Y.B.; Jang, H.C. Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis. Atherosclerosis 2015, 243, 107–119.
  37. He, X.; Liu, W.; Shi, M.; Yang, Z.; Zhang, X.; Gong, P. Docosahexaenoic acid attenuates LPS-stimulated inflammatory response by regulating the PPARγ/NF-κB pathways in primary bovine mammary epithelial cells. Res. Vet. Sci. 2017, 112, 7–12.
  38. Linghu, K.G.; Wu, G.P.; Fu, L.Y.; Yang, H.; Li, H.Z.; Chen, Y.; Yu, H.; Tao, L.; Shen, X.C. 1,8-Cineole Ameliorates LPS-Induced Vascular Endothelium Dysfunction in Mice via PPAR-γ Dependent Regulation of NF-κB. Front. Pharmacol. 2019, 10, 178.
  39. Song, Y.; Zhao, H.; Liu, J.; Fang, C.; Miao, R. Effects of Citral on Lipopolysaccharide-Induced Inflam-mation in Human Umbilical Vein Endothelial Cells. Inflammation 2016, 39, 663–671.
  40. Katsukawa, M.; Nakata, R.; Koeji, S.; Hori, K.; Takahashi, S.; Inoue, H. Citronellol and geraniol, components of rose oil, activate peroxisome proliferator-activated receptor α and γ and suppress cyclooxygenase-2 expression. Biosci. Biotechnol. Biochem. 2011, 75, 1010–1012.
  41. Hwa, J.S.; Mun, L.; Kim, H.J.; Seo, H.G.; Lee, J.H.; Kwak, J.H.; Lee, D.-U.; Chang, K.C. Genipin Selectively Inhibits TNF-α-activated VCAM-1 But Not ICAM-1 Expression by Upregulation of PPAR-γ in Human Endothelial Cells. Korean J. Physiol. Pharmacol. 2011, 15, 157–162.
  42. Zhang, X.; Fernández-Hernando, C. Endothelial HMGB1 (High-Mobility Group Box 1) Regulation of LDL (Low-Density Lipoprotein) Transcytosis: A Novel Mechanism of Intracellular HMGB1 in Atherosclerosis. Arter. Thromb. Vasc. Biol. 2020, 41, 217–219.
  43. Kim, N.; Kim, C.; Ryu, S.H.; Lee, W.; Bae, J.-S. Anti-Septic Functions of Cornuside against HMGB1-Mediated Severe Inflammatory Responses. Int. J. Mol. Sci. 2022, 23, 2065.
  44. Li, J.Z.; Wu, J.H.; Yu, S.Y.; Shao, Q.R.; Dong, X.M. Inhibitory effects of paeoniflorin on lysophosphati-dylcholine-induced inflammatory factor production in human umbilical vein endothelial cells. Int. J. Mol. Med. 2013, 31, 493–497.
  45. Nishikawa, T.; Edelstein, D.; Brownlee, M. The missing link: A single unifying mechanism for diabetic complications. Kidney Int. 2000, 58, S26–S30.
  46. Wang, G.F.; Wu, S.Y.; Xu, W.; Jin, H.; Zhu, Z.G.; Li, Z.H.; Tian, Y.X.; Zhang, J.J.; Rao, J.J.; Wu, S.G. Geniposide inhibits high glu-cose-induced cell adhesion through the NF-kappaB signaling pathway in human umbilical vein endothelial cells. Acta Pharmacol. Sin. 2010, 31, 953–962.
  47. Bi, Y.; Han, X.; Lai, Y.; Fu, Y.; Li, K.; Zhang, W.; Wang, Q.; Jiang, X.; Zhou, Y.; Liang, H.; et al. Systems pharmacological study based on UHPLC-Q-Orbitrap-HRMS, network pharmacology and experimental validation to explore the potential mechanisms of Danggui-Shaoyao-San against atherosclerosis. J. Ethnopharmacol. 2021, 278, 114278.
  48. Liu, H.T.; He, J.L.; Li, W.M.; Yang, Z.; Wang, Y.X.; Yin, J.; Du, Y.G.; Yu, C. Geniposide inhibits interleukin-6 and interleukin-8 production in lipopolysaccharide-induced human umbilical vein endothelial cells by blocking p38 and ERK1/2 signaling pathways. Inflamm. Res. 2010, 59, 451–461.
  49. Zhang, C.; Syed, T.W.; Liu, R.; Yu, J. Role of Endoplasmic Reticulum Stress, Autophagy, and Inflammation in Cardiovascular Disease. Front. Cardiovasc. Med. 2017, 4, 29.
  50. Chen, J.; Zhang, M.; Zhu, M.; Gu, J.; Song, J.; Cui, L.; Liu, D.; Ning, Q.; Jia, X.; Feng, L. Paeoniflorin prevents endoplasmic reticulum stress-associated inflammation in lipopolysaccharide -stimulated human umbilical vein endothelial cells via the IRE1α/NF-κB signaling pathway. Food Funct. 2018, 9, 2386–2397.
  51. Hu, H.; Wang, C.; Jin, Y.; Meng, Q.; Liu, Q.; Liu, Z.; Liu, K.; Liu, X.; Sun, H. Catalpol Inhibits Homocysteine-induced Ox-idation and Inflammation via Inhibiting Nox4/NF-κB and GRP78/PERK Pathways in Human Aorta Endothelial Cells. Inflammation 2019, 42, 64–80.
  52. Wang, Y.; Che, J.; Zhao, H.; Tang, J.; Shi, G. Paeoniflorin attenuates oxidized low-density lipoprotein-induced apoptosis and adhesion molecule expression by autophagy enhancement in human umbilical vein endothelial cells. J. Cell. Biochem. 2018, 120, 9291–9299.
  53. Zhang, Q.; Liu, J.; Duan, H.; Li, R.; Peng, W.; Wu, C. Activation of Nrf2/HO-1 signaling: An important molecular mechanism of herbal medicine in the treatment of atherosclerosis via the protection of vascular endothelial cells from oxidative stress. J. Adv. Res. 2021, 34, 43–63.
  54. Wang, X.; Zhao, S.; Su, M.; Sun, L.; Zhang, S.; Wang, D.; Liu, Z.; Yuan, Y.; Liu, Y.; Li, Y. Geraniol improves endothelial function by inhibiting NOX-2 derived oxidative stress in high fat diet fed mice. Biochem. Biophys. Res. Commun. 2016, 474, 182–187.
  55. Song, S.; Xiao, X.; Guo, D.; Mo, L.; Bu, C.; Ye, W.; Den, Q.; Liu, S.; Yang, X. Protective effects of Paeoniflorin against AOPP-induced oxidative injury in HUVECs by blocking the ROS-HIF-1α/VEGF pathway. Phytomedicine 2017, 34, 115–126.
  56. Lu, Y.W.; Hao, R.J.; Wei, Y.Y.; Yu, G.R. The protective effect of harpagoside on angiotensin II (Ang II )-induced blood–brain barrier leakage in vitro. Phytother. Res. 2021, 35, 6241–6254.
  57. Zhou, S.; Sun, Y.; Zhao, K.; Gao, Y.; Cui, J.; Qi, L.; Huang, L. miR-21/PTEN pathway mediates the car-dioprotection of geniposide against oxidized low-density lipoprotein-induced endothelial injury via suppressing oxidative stress and inflammatory response. Int. J. Mol. Med. 2020, 45, 1305–1316.
  58. Jiang, F.; Xu, X.R.; Li, W.M.; Xia, K.; Wang, L.F.; Yang, X.C. Monotropein alleviates H2O2-induced inflammation, oxidative stress and apoptosis via NF-κB/AP-1 signaling. Mol. Med. Rep. 2020, 22, 4828–4836.
  59. El-Agamy, D.S.; A Nader, M. Attenuation of oxidative stress-induced vascular endothelial dysfunction by thymoquinone. Exp. Biol. Med. 2012, 237, 1032–1038.
  60. Yu, L.; Liu, H. Perillaldehyde prevents the formations of atherosclerotic plaques through recoupling endothelial nitric oxide synthase. J. Cell. Biochem. 2018, 119, 10204–10215.
  61. Lu, J.X.; Guo, C.; Ou, W.S.; Jing, Y.; Niu, H.F.; Song, P.; Li, Q.Z.; Liu, Z.; Xu, J.; Li, P.; et al. Citronellal prevents endothelial dysfunction and ath-erosclerosis in rats. J. Cell. Biochem. 2019, 120, 3790–3800.
  62. Jiang, J.; Dong, C.; Zhai, L.; Lou, J.; Jin, J.; Cheng, S.; Chen, Z.; Guo, X.; Lin, D.; Ding, J.; et al. Paeoniflorin Suppresses TBHP-Induced Oxidative Stress and Apoptosis in Human Umbilical Vein Endothelial Cells via the Nrf2/HO-1 Signaling Pathway and Im-proves Skin Flap Survival. Front. Pharmacol. 2021, 12, 735530.
  63. Liu, X.; Xu, Y.; Cheng, S.; Zhou, X.; Zhou, F.; He, P.; Hu, F.; Zhang, L.; Chen, Y.; Jia, Y. Geniposide Combined With Noto-ginsenoside R1 Attenuates Inflammation and Apoptosis in Atherosclerosis via the AMPK/mTOR/Nrf2 Signaling Pathway. Front. Pharmacol. 2021, 12, 687394.
  64. Liu, J.-Y.; Zhang, D.-J. Amelioration by Catalpol of Atherosclerotic Lesions in Hypercholesterolemic Rabbits. Planta Med. 2015, 81, 175–184.
  65. Jayachandran, M.; Chandrasekaran, B.; Namasivayam, N. Geraniol attenuates oxidative stress by Nrf2 activation in diet-induced experimental atherosclerosis. J. Basic Clin. Physiol. Pharmacol. 2015, 26, 335–346.
  66. Peng, J.; Jiang, Z.; Wu, G.; Cai, Z.; Du, Q.; Tao, L.; Zhang, Y.; Chen, Y.; Shen, X. Improving protection effects of eucalyptol via carboxymethyl chitosan-coated lipid nanoparticles on hyperglycaemia-induced vascular endothelial injury in rats. J. Drug Target. 2020, 29, 520–530.
  67. Jazbutyte, V.; Thum, T. MicroRNA-21: From Cancer to Cardiovascular Disease. Curr. Drug Targets 2010, 11, 926–935.
  68. Yang, Q.; Yang, K.; Li, A. microRNA-21 protects against ischemia-reperfusion and hypoxia-reperfusion-induced cardiocyte apoptosis via the phosphatase and tensin homolog/Akt-dependent mechanism. Mol. Med. Rep. 2014, 9, 2213–2220.
  69. Zhang, J.Y.; Ma, J.; Yu, P.; Tang, G.J.; Li, C.J.; Yu, D.M.; Zhang, Q.M. Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN. Am. J. Transl. Res. 2017, 9, 3935–3949.
  70. Hung, C.H.; Chan, S.H.; Chu, P.M.; Tsai, K.L. Homocysteine facilitates LOX-1 activation and endothelial death through the PKCβ and SIRT1/HSF1 mechanism: Relevance to human hyperhomocysteinaemia. Clin. Sci. 2015, 129, 477–487.
  71. Chen, X.-P.; Xun, K.-L.; Wu, Q.; Zhang, T.-T.; Shi, J.-S.; Du, G.-H. Oxidized low density lipoprotein receptor-1 mediates oxidized low density lipoprotein-induced apoptosis in human umbilical vein endothelial cells: Role of reactive oxygen species. Vasc. Pharmacol. 2007, 47, 1–9.
  72. Wang, Y.; Hong, Y.; Zhang, C.; Shen, Y.; Pan, Y.S.; Chen, R.Z.; Zhang, Q.; Chen, Y.H. Picroside II attenuates hyper-homocysteinemia-induced endothelial injury by reducing inflammation, oxidative stress and cell apoptosis. J. Cell. Mol. Med. 2019, 23, 464–475.
  73. Chen, J.Y.; Ye, Z.X.; Wang, X.F.; Chang, J.; Yang, M.W.; Zhong, H.H.; Hong, F.F.; Yang, S.L. Nitric oxide bioavailability dys-function involves in atherosclerosis. Biomed. Pharmacother. 2018, 97, 423–428.
  74. Förstermann, U.; Xia, N.; Li, H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Athero-sclerosis. Circ. Res. 2017, 120, 713–735.
  75. Sun, W.; Gao, Y.; Ding, Y.; Cao, Y.; Chen, J.; Lv, G.; Lu, J.; Yu, B.; Peng, M.; Xu, H.; et al. Catalpol ameliorates advanced glycation end product-induced dysfunction of glomerular endothelial cells via regulating nitric oxide synthesis by inducible nitric oxide synthase and endothelial nitric oxide synthase. IUBMB Life 2019, 71, 1268–1283.
  76. Wu, J.; Zhang, D.; Hu, L.; Zheng, X.; Chen, C. Paeoniflorin alleviates NG-nitro-L-arginine methyl ester (L-NAME)-induced gestational hypertension and upregulates silent information regulator 2 related enzyme 1 (SIRT1) to reduce H2O2-induced endothelial cell damage. Bioengineered 2022, 13, 2248–2258.
  77. Linghu, K.; Lin, D.; Yang, H.; Xu, Y.; Zhang, Y.; Tao, L.; Chen, Y.; Shen, X. Ameliorating effects of 1,8-cineole on LPS-induced human umbilical vein endothelial cell injury by suppressing NF-κB signaling in vitro. Eur. J. Pharmacol. 2016, 789, 195–201.
  78. Qiu, Y.; Chao, C.Y.; Jiang, L.; Zhang, J.; Niu, Q.Q.; Guo, Y.Q.; Song, Y.T.; Li, P.; Zhu, M.L.; Yin, Y.L. Citronellal alleviate macro- and micro-vascular damage in high fat diet/streptozotocin-Induced diabetic rats via a S1P/S1P1 dependent signaling pathway. Eur. J. Pharmacol. 2022, 920, 174796.
  79. Lee, G.-H.; Lee, H.-Y.; Choi, M.-K.; Choi, A.-H.; Shin, T.-S.; Chae, H.-J. Eucommia ulmoides leaf (EUL) extract enhances NO production in ox-LDL-treated human endothelial cells. Biomed. Pharmacother. 2018, 97, 1164–1172.
  80. Duan, H.; Zhang, Q.; Liu, J.; Li, R.; Wang, D.; Peng, W.; Wu, C. Suppression of apoptosis in vascular endothelial cell, the promising way for natural medicines to treat atherosclerosis. Pharmacol. Res. 2021, 168, 105599.
  81. Datta, A.; Sarmah, D.; Mounica, L.; Kaur, H.; Kesharwani, R.; Verma, G.; Veeresh, P.; Kotian, V.; Kalia, K.; Borah, A.; et al. Cell Death Pathways in Ischemic Stroke and Targeted Pharmacotherapy. Transl. Stroke Res. 2020, 11, 1185–1202.
  82. Paone, S.; Baxter, A.A.; Hulett, M.D.; Poon, I.K.H. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell. Mol. Life Sci. 2019, 76, 1093–1106.
  83. Liu, Y.; Sun, Y.; Bai, X.; Li, L.; Zhu, G. Albiflorin Alleviates Ox-LDL-Induced Human Umbilical Vein En-dothelial Cell Injury through IRAK1/TAK1 Pathway. Biomed. Res. Int. 2022, 2022, 6584645.
  84. Rahiman, N.; Akaberi, M.; Sahebkar, A.; Emami, S.A.; Tayarani-Najaran, Z. Protective effects of saffron and its active components against oxidative stress and apoptosis in endothelial cells. Microvasc. Res. 2018, 118, 82–89.
  85. Hu, L.; Sun, Y.; Hu, J. Catalpol inhibits apoptosis in hydrogen peroxide-induced endothelium by activating the PI3K/Akt signaling pathway and modulating expression of Bcl-2 and Bax. Eur. J. Pharmacol. 2010, 628, 155–163.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback